title: Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB.
abstract: S100betabeta is a calcium binding, neurotrophic protein produced by nonneuronal cells in the nervous system. The pathway by which it enhances neuronal survival is unknown. Here we show that S100betabeta enhances survival of embryonic chick forebrain neurons in a dose-dependent manner. In the presence of suboptimal amounts of S100betabeta, neuronal survival is enhanced by the immunosuppressants FK506 and cyclosporin A at concentrations that inhibit calcineurin, which is present in these cells. Rapamycin, an immunosuppressant that does not inhibit calcineurin, did not enhance cell survival. Cypermethrin, a direct and highly specific calcineurin inhibitor, mimicked the immunophilin ligands in its neurotrophic effect. None of the drugs stimulated neuronal survival in the absence of S100betabeta. In the presence of suboptimal amounts of S100betabeta, FK506, cyclosporin A, and cypermethrin (but not rapamycin) also increased NF-kappaB activity, as measured by immunofluorescence of cells stained with antibody to the active subunit (p65) and by immunoblotting of nuclear extracts. Antioxidant and glucocorticoid inhibitors of NF-kappaB decreased both the amount of active NF-kappaB and the survival of neurons caused by S100betabeta alone or in the presence of augmenting drugs. We conclude that S100betabeta enhances the survival of chick embryo forebrain neurons through the activation of NF-kappaB.
authors.affiliation: Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, Colorado 80523-1870, USA.
authors.forename: A R
authors.initials: AR
authors.lastname: Alexanian
authors.forename: J R
authors.initials: JR
authors.lastname: Bamburg
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001923:Brain Chemistry; D065095:Calcineurin Inhibitors; D002135:Calcium-Binding Proteins / Q000302:isolation & purification / Q000494:pharmacology / Q000502:physiology*; D002417:Cattle; D002467:Cell Nucleus / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D002642:Chick Embryo; D003374:Coumarins / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology; D019281:Dimerization; D020104:Immunophilins / Q000502:physiology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D049934:Isocoumarins; D046911:Macromolecular Substances; D016328:NF-kappa B / Q000378:metabolism*; D009414:Nerve Growth Factors / Q000302:isolation & purification / Q000494:pharmacology / Q000502:physiology*; D009474:Neurons / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D016548:Prosencephalon / Q000166:cytology*; D011722:Pyrethrins / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D020123:Sirolimus / Q000494:pharmacology; D016559:Tacrolimus / Q000494:pharmacology*; D013859:Thiocarbamates / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D065095:Calcineurin Inhibitors; D002135:Calcium-Binding Proteins; D003374:Coumarins; D007166:Immunosuppressive Agents; D049934:Isocoumarins; D046911:Macromolecular Substances; D016328:NF-kappa B; D009414:Nerve Growth Factors; D011722:Pyrethrins; D011759:Pyrrolidines; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D015842:Serine Proteinase Inhibitors; D013859:Thiocarbamates; C017160:cypermethrin; C020972:pyrrolidine dithiocarbamic acid; C046235:3,4-dichloroisocoumarin; D003907:Dexamethasone; D016572:Cyclosporine; D020104:Immunophilins; D020123:Sirolimus; D016559:Tacrolimus